Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494896 · ClinicalTrials.gov registry record
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
A clinical trial, sponsored by University of Florida.
- Terminated
- Registry status
- 9
- Enrollment target
NCT01494896 is a clinical trial that was terminated before completion, run by University of Florida. The registered enrollment target is 9 participants.
The verdict
NCT01494896 was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to see how inhaled treprostinil sodium (Tyvaso) affects the amount of air and blood that reach the alveoli, or tiy air sacs, in the lungs of patients with Group 1 Pulmonary Arterial Hypertension with concomitant Chronic Obstructive Pulmonary Disease (COPD).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494896
The ClinicalTrials.gov registry entry for NCT01494896 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01494896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494896 about?
NCT01494896 is a clinical study titled "Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching". The purpose of this study is to see how inhaled treprostinil sodium (Tyvaso) affects the amount of air and blood that reach the alveoli, or tiy air sacs, in the lungs of patients with Group 1 Pulmonary Arterial Hypertension with concomitant Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT01494896?
This trial is currently terminated. The enrollment target is 9 participants. The study started on 2011-11. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01494896?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.